Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A
Format:	Journal article
Język:	English
Wydane:	Springer Nature 2020

Podobne zapisy

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
od: Fidler, C, i wsp.
Wydane: (2004)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
od: Ramy Rahmé, i wsp.
Wydane: (2023-04-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
od: Čolović Nataša, i wsp.
Wydane: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
od: Lijuan Zhang, i wsp.
Wydane: (2023-12-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
od: Haase, D, i wsp.
Wydane: (2019)

SF3B1 mutant myelodysplastic syndrome: Recent advances
od: Pellagatti, A, i wsp.
Wydane: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
od: Pimjai Niparuck, i wsp.
Wydane: (2021-10-01)

Gene expression profiling in the myelodysplastic syndromes.
od: Pellagatti, A, i wsp.
Wydane: (2005)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
od: Pellagatti, A, i wsp.
Wydane: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
od: Davidson Zhao, i wsp.
Wydane: (2023-03-01)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (2014)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
od: Daver, NG, i wsp.
Wydane: (2022)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
od: Laurence Lodé, i wsp.
Wydane: (2018-01-01)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
od: Rashmi Kanagal-Shamanna, i wsp.
Wydane: (2021-03-01)

A tale of two alleles: TP53 and transformation in MPNs
od: Brierley, C, i wsp.
Wydane: (2022)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
od: Liberante, F, i wsp.
Wydane: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
od: Liberante, F, i wsp.
Wydane: (2013)

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should
od: Corey Cutler
Wydane: (2017-12-01)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
od: Fernando Barroso Duarte, i wsp.
Wydane: (2017-05-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
od: Armstrong, R, i wsp.
Wydane: (2017)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
od: Nikeeta Mandhan, i wsp.
Wydane: (2022-01-01)

Clonality in the myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (2001)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
od: David A. Sallman
Wydane: (2020-06-01)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
od: Y. Fang, i wsp.
Wydane: (2022-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
od: Shyam A. Patel, i wsp.
Wydane: (2023-11-01)

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
od: Yi Chen, i wsp.
Wydane: (2023-11-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
od: Kathy L. McGraw, i wsp.
Wydane: (2016-08-01)

Molecular pathogenesis of the myelodysplastic syndromes
od: Boultwood, J, i wsp.
Wydane: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
od: Melania Tesio
Wydane: (2023-02-01)

Telomere length in myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (1995)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
od: Nabih Maslah, i wsp.
Wydane: (2020-06-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
od: Yuxin Wang, i wsp.
Wydane: (2022-07-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
od: Pellagatti, A, i wsp.
Wydane: (2003)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
od: Haiwei Wang, i wsp.
Wydane: (2022-06-01)

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia
od: Doolittle, H
Wydane: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
od: Alexander Quaas, i wsp.
Wydane: (2019-01-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
od: Pellagatti, A, i wsp.
Wydane: (2008)

P066: Variant overlooked: A partial deficiency TP53 allele that skirts interpretation criteria
od: Lisa Lansdon, i wsp.
Wydane: (2023-01-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
od: Papaemmanuil, E, i wsp.
Wydane: (2013)